Tìm theo
Elacridar
antineoplastics adjuncts
Thuốc Gốc
Small Molecule
CAS: 143664-11-3
CTHH: C34H33N3O5
PTK: 563.6429
Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C34H33N3O5
Phân tử khối
563.6429
Monoisotopic mass
563.242021181
InChI
InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)
InChI Key
InChIKey=OSFCMRGOZNQUSW-UHFFFAOYSA-N
IUPAC Name
N-{4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}-5-methoxy-9-oxo-9,10-dihydroacridine-4-carboxamide
Traditional IUPAC Name
N-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl}-5-methoxy-9-oxo-10H-acridine-4-carboxamide
SMILES
COC1=CC=CC2=C1NC1=C(C=CC=C1C(=O)NC1=CC=C(CCN3CCC4=CC(OC)=C(OC)C=C4C3)C=C1)C2=O
Độ hòa tan
2.81e-03 g/l
logP
6.81
logS
-5.3
pKa (strongest acidic)
12.06
pKa (Strongest Basic)
8.35
PSA
89.13 Å2
Refractivity
165.2 m3·mol-1
Polarizability
63.43 Å3
Rotatable Bond Count
8
H Bond Acceptor Count
7
H Bond Donor Count
2
Physiological Charge
1
Number of Rings
6
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors.
Cơ Chế Tác Dụng : Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued. P-glycoprotein is a well characterized human ABC-transporter of the MDR/TAP subfamily. It is an ATP-dependent efflux pump with broad substrate specificity. It likely evolved as a defence mechanism against harmful substances. Increased intestinal expression of P-glycoprotein can reduce the absorption of drugs that are substrates for P-glycoprotein. Thus, there is a reduced bioavailability, therapeutic plasma concentrations are not attained. Elacridar functions by inhibiting P-glycoprotein, resulting in an increased bioavailability of coadminstered drugs.
Chỉ Định : For the treatment of solid tumors.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB04881
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=119373
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=10238466
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D03968
ChemSpider
http://www.chemspider.com/Chemical-Structure.106620.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50206310
... loading
... loading